Source:http://linkedlifedata.com/resource/pubmed/id/15318008
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
7
|
| pubmed:dateCreated |
2005-9-29
|
| pubmed:abstractText |
The new meningococcal C conjugate vaccine became available in Spain and was included in the infant vaccination schedule in 2000. A catch-up campaign was carried out in children under six years of age. As a consequence, the incidence of meningococcal disease caused by serogroup C has fallen sharply during the last three epidemiological years in Spain. The risk of contracting serogroup C disease in 2002/2003 fell by 58% when compared with the season before the conjugate vaccine was introduced. There was also an important decrease in mortality. Three deaths due to serogroup C occurred in the age groups targeted for vaccination in 2002/2003, compared with 30 deaths in the same age groups in the season before the launch of the vaccine campaign. In the catch-up campaign the vaccine coverage reached values above 92%. For the 2001, 2002 and 2003 routine childhood immunisation programme coverage values ranged from 90% to 95%. During the past three years a total of 111 cases of serogroup C disease have been reported in patients in the vaccine target group. Most of the vaccination failures occurred during the epidemiological year 2002/2003. Eight (53%) vaccine failures occurred in children who had been routinely immunised in infancy, and could be related to a lost of protection with time since vaccination. The isolation of several B:2a:P1.5 strains (ST-11 lineage) is noteworthy. These may have their origin in C:2a:P1.5 strains which, after undergoing genetic recombination at the capsular operon level, express serogroup B. These strains could have relevant epidemic potential.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Jul
|
| pubmed:issn |
1560-7917
|
| pubmed:author | |
| pubmed:issnType |
Electronic
|
| pubmed:volume |
9
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
11-5
|
| pubmed:dateRevised |
2009-11-19
|
| pubmed:meshHeading |
pubmed-meshheading:15318008-Adolescent,
pubmed-meshheading:15318008-Adult,
pubmed-meshheading:15318008-Aged,
pubmed-meshheading:15318008-Aged, 80 and over,
pubmed-meshheading:15318008-Child,
pubmed-meshheading:15318008-Child, Preschool,
pubmed-meshheading:15318008-Female,
pubmed-meshheading:15318008-Humans,
pubmed-meshheading:15318008-Incidence,
pubmed-meshheading:15318008-Infant,
pubmed-meshheading:15318008-Infant, Newborn,
pubmed-meshheading:15318008-Male,
pubmed-meshheading:15318008-Mass Vaccination,
pubmed-meshheading:15318008-Meningitis, Meningococcal,
pubmed-meshheading:15318008-Meningococcal Vaccines,
pubmed-meshheading:15318008-Middle Aged,
pubmed-meshheading:15318008-Outcome Assessment (Health Care),
pubmed-meshheading:15318008-Population Surveillance,
pubmed-meshheading:15318008-Risk Assessment,
pubmed-meshheading:15318008-Risk Factors,
pubmed-meshheading:15318008-Seasons,
pubmed-meshheading:15318008-Spain,
pubmed-meshheading:15318008-Treatment Outcome,
pubmed-meshheading:15318008-Vaccination
|
| pubmed:year |
2004
|
| pubmed:articleTitle |
Impact of the meningococcal C conjugate vaccine in Spain: an epidemiological and microbiological decision.
|
| pubmed:affiliation |
Centro Nacional de Epidemiología, Instituto de Salud Carlos III, Madrid, Spain.
|
| pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|